Department of Urology, Loma Linda University Medical Center, Loma Linda, California.
Patients with end-stage renal disease (ESRD) have multiple comorbidities that place them at increased risk for surgical complications. Consequently, patients with both ESRD and prostate cancer (PCa) have rarely been considered candidates for radical prostatectomy. The objective of this study is to compare ESRD patients who are undergoing robot-assisted laparoscopic prostatectomy (RALP) with a cohort of patients with no history of dialysis.
A retrospective review was conducted of 430 patients who were undergoing RALP, including 12 receiving dialysis at the time of surgery. Preoperative demographics, perioperative parameters, and postoperative outcomes were compared using a two-tailed Student t test and a chi-square test, with significance at P< 0.05.
Patient demographics including body mass index, Gleason score, and prostate-specific antigen (PSA) value were similar between the two groups. Patients with ESRD had younger age (55.5 vs 62.9 years; P< 0.01), higher American Society of Anesthesiologists scores (3.7 vs 2.5; P< 0.01), and higher age-adjusted Charlson Comorbidity Index scores (6.2 vs 4.2; P< 0.01). Patient outcomes including operative time, estimated blood loss, complication rate, postoperative stay, and positive margins did not differ significantly between groups. No ESRD patients needed pads or had a detectable PSA level using an ultrasensitive assay.
This series represents the largest series of patients with ESRD undergoing RALP. These patients experienced similar outcomes compared with patients with no history of dialysis despite greater preoperative comorbidity. RALP produces minimal fluid shifts, low blood loss, and excellent cancer control, making it an ideal treatment option to prepare patients with both ESRD and PCa for renal transplantation.
Written by:
Heldt JP, Jellison FC, Yuen WD, Tenggardjaja CF, Lui PD, Ruckle HC, Barker GR, Baldwin DD. Are you the author?
Reference: J Endourol. 2011 May 25. Epub ahead of print.
doi: 10.1089/end.2010.0680
PubMed Abstract
PMID: 21612432
UroToday.com Prostate Cancer Section
